Literature DB >> 30859413

Tagraxofusp: First Global Approval.

Yahiya Y Syed1.   

Abstract

Tagraxofusp (tagraxofusp-erzs) [Elzonris™] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). In December 2018, tagraxofusp received its first global approval in the USA for the treatment of BPDCN in adults and in paediatric patients aged 2 years and older. A centralized registration application for the use of tagraxofusp in patients with BPDCN is under review in the EU. This article summarizes the milestones in the development of tagraxofusp leading to its first global approval for the treatment of BPDCN.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30859413     DOI： 10.1007/s40265-019-01087-z

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  10 in total

1.  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Naveen Pemmaraju; Bruno C Medeiros; Hetty E Carraway; Olga Frankfurt; Stephen J Forman; Xuezhong A Yang; Marina Konopleva; Francine Garnache-Ottou; Fanny Angelot-Delettre; Christopher Brooks; Michael Szarek; Eric Rowinsky
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Blastic plasmacytoid dendritic cell neoplasm.

Authors:  Naveen Pemmaraju
Journal:  Clin Adv Hematol Oncol       Date:  2016-04

3.  A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.

Authors:  A Ray; D S Das; Y Song; V Macri; P Richardson; C L Brooks; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2017-05-08       Impact factor: 11.528

4.  In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Authors:  Fanny Angelot-Delettre; Anne Roggy; Arthur E Frankel; Baptiste Lamarthee; Estelle Seilles; Sabeha Biichle; Bernard Royer; Eric Deconinck; Eric K Rowinsky; Christopher Brooks; Valerie Bardet; Blandine Benet; Hind Bennani; Zehaira Benseddik; Agathe Debliquis; Daniel Lusina; Mikael Roussel; Françoise Solly; Michel Ticchioni; Philippe Saas; Francine Garnache-Ottou
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

5.  Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor.

Authors:  A E Frankel; J Ramage; M Kiser; R Alexander; G Kucera; M S Miller
Journal:  Protein Eng       Date:  2000-08

6.  A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.

Authors:  Hyun Pyo Kim; Arthur E Frankel; Donna E Hogge
Journal:  Leuk Res       Date:  2010-08       Impact factor: 3.156

7.  The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.

Authors:  Donna E Hogge; Michaela Feuring-Buske; Brigitte Gerhard; Arthur E Frankel
Journal:  Leuk Res       Date:  2004-11       Impact factor: 3.156

8.  Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.

Authors:  Arthur Frankel; Jen-Sing Liu; David Rizzieri; Donna Hogge
Journal:  Leuk Lymphoma       Date:  2008-03

9.  First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.

Authors:  Weili Sun; Huaying Liu; Young Kim; Nicole Karras; Anna Pawlowska; Debbie Toomey; Wade Kyono; Paul Gaynon; Joseph Rosenthal; Anthony Stein
Journal:  J Hematol Oncol       Date:  2018-05-02       Impact factor: 17.388

10.  The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.

Authors:  Rajeswaran Mani; Swagata Goswami; Bhavani Gopalakrishnan; Rahul Ramaswamy; Ronni Wasmuth; Minh Tran; Xiaokui Mo; Amber Gordon; Donna Bucci; David M Lucas; Alice Mims; Christopher Brooks; Adrienne Dorrance; Alison Walker; William Blum; John C Byrd; Gerard Lozanski; Sumithira Vasu; Natarajan Muthusamy
Journal:  Haematologica       Date:  2018-05-17       Impact factor: 9.941
  10 in total
  11 in total

1.  Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.

Authors:  Ping Chen; Brandon M Bordeau; Yu Zhang; Joseph P Balthasar
Journal:  Mol Cancer Ther       Date:  2022-10-07       Impact factor: 6.009

2.  Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models.

Authors:  Shijing Wang; Hui Wen; Wenyi Fei; Yuhong Zhao; Yuqi Feng; Lu Kuang; Min Wang; Min Wu
Journal:  Am J Cancer Res       Date:  2020-08-01       Impact factor: 5.942

3.  Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy.

Authors:  Zehra Narli Ozdemir; Guldane Cengiz Seval; Ugur Sahin; Atilla Uslu; Mehmet Gunduz; Sinem Civriz Bozdag; Selami Kocak Toprak; Meltem Kurt Yuksel; Pervin Topcuoglu; Isinsu Kuzu; Muhit Ozcan; Gunhan Gurman; Osman Ilhan
Journal:  Indian J Hematol Blood Transfus       Date:  2020-07-04       Impact factor: 0.900

Review 4.  Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.

Authors:  Minas P Economides; Marina Konopleva; Naveen Pemmaraju
Journal:  Ther Adv Hematol       Date:  2019-09-23

Review 5.  Targeted Diphtheria Toxin-Based Therapy: A Review Article.

Authors:  Fatemeh Shafiee; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Microbiol       Date:  2019-10-18       Impact factor: 5.640

6.  Blastic plasmacytoid dendritic cell neoplasm with skin and bone marrow involvement: Report of three cases.

Authors:  Jiang-Hong Guo; Hong-Wei Zhang; Li Wang; Wei Bai; Jin-Fen Wang
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

7.  Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.

Authors:  Tianyu Cai; Agnès Gouble; Kathryn L Black; Anna Skwarska; Ammar S Naqvi; Deanne Taylor; Ming Zhao; Qi Yuan; Mayumi Sugita; Qi Zhang; Roman Galetto; Stéphanie Filipe; Antonio Cavazos; Lina Han; Vinitha Kuruvilla; Helen Ma; Connie Weng; Chang-Gong Liu; Xiuping Liu; Sergej Konoplev; Jun Gu; Guilin Tang; Xiaoping Su; Gheath Al-Atrash; Stefan Ciurea; Sattva S Neelapu; Andrew A Lane; Hagop Kantarjian; Monica L Guzman; Naveen Pemmaraju; Julianne Smith; Andrei Thomas-Tikhonenko; Marina Konopleva
Journal:  Nat Commun       Date:  2022-04-28       Impact factor: 17.694

8.  Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma.

Authors:  Guiqin Xie; Liang Shan; Yuanyi Liu; Tzyy-Choou Wu; Xinbin Gu
Journal:  Biology (Basel)       Date:  2022-03-22

9.  Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus.

Authors:  Jing Tang; Xuqian Ma; Xin Chen; Mingqian Feng; Xin Jin; Ke Wang; Jixi Wan; Xianmin Zhu; Rong Xie; Shuang Dong; Sheng Hu; Hui Jiang; Conghua Xie
Journal:  Ann Transl Med       Date:  2022-07

Review 10.  Targeting Receptors on Cancer Cells with Protein Toxins.

Authors:  Antonella Antignani; Eric Chun Hei Ho; Maria Teresa Bilotta; Rong Qiu; Robert Sarnvosky; David J FitzGerald
Journal:  Biomolecules       Date:  2020-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.